Features Partner Sites Information LinkXpress
Sign In
Demo Company

Novel Technique Improves Investigation of Interactions Between HIV and Malaria Parasite

By BiotechDaily International staff writers
Posted on 27 Aug 2012
Print article
A new video article describes a novel technique used to study the interactions between HIV-1 and Plasmodium falciparum in cultured human cells, allowing scientists to explore different parameters of coinfection by the two microbes.

Due to their extensive overlap in some developing regions, especially Sub-Saharan Africa, coinfections with malaria and HIV-1 are common, but the interplay between the two diseases is poorly understood and a systematic analysis of the interactions in different relevant human primary cell populations is critically needed. Each disease affects the immune system differently and by studying coinfection at different phases of each disease in vitro, scientists can better understand how different stages of malaria infection and HIV reproduction affect the onset and severity of the other disease.

In this study, an in vitro Plasmodium-HIV-1 coinfection model was developed and used to investigate the impact of P. falciparum-infected red blood cells on the HIV-1 replicative cycle in human primary monocyte-derived macrophages (MDMs). The impact of parasite exposure on HIV-1 transcriptional/translational events was monitored by using single cycle pseudotyped viruses in which a luciferase reporter gene has replaced the Env gene, while the effect on the quantity of progeny virus released by the infected macrophages is determined by measuring the HIV-1 capsid protein p24 by ELISA in cell supernatants. The researchers observed that exposure of P. falciparum to MDMs, decreases their susceptibility to HIV-1 infection, exerting a clear detrimental effect on the HIV-1 replicative cycle in macrophages (not excluding the possibility of other effects under different conditions).

The new technique, developed and applied by the laboratory led by Dr. David Richard of the Centre Hospitalier Universitaire de Quebec (CHUQ; Quebec City, Quebec, CA; www.chuq.qc.ca), was published August 15, 2012, in the online video Journal of Visualized Experiments (JoVE). "By publishing in JoVE, you really see what is happening in the experiment. The visual representation helps succinctly explain a long procedure, and gives you a fuller picture of the schematic complexity," said Dr. Richards. He hopes that this publication will give the scientific community an important additional tool to look at the interactions of the coinfection encounter on a cellular level and to more thoroughly dissect these interactions in a simplified system. This versatile system can also be adapted to monitor other factors and to use other primary cell types susceptible to HIV-1 infection. "Publication of the protocol in JoVE will allow researchers around the world to see a detailed demonstration of this system, which will help bring the technology to their laboratories," said JoVE editor Dr. Charlotte Frank Sage.

Related Links:

Centre Hospitalier Universitaire de Quebec
Journal of Visualized Experiments

Print article



view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

How Blocking TROY Signaling Slows Brain Cancer Growth

Cancer researchers have found how the low molecular weight drug propentofylline (PPF) slows the growth of the aggressive brain tumor glioblastoma multiforme (GBM). This form of brain cancer is the most... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.